305 related articles for article (PubMed ID: 30247102)
1. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States.
Sharma D; Xing S; Hung YT; Caskey RN; Dowell ML; Touchette DR
Orphanet J Rare Dis; 2018 Sep; 13(1):172. PubMed ID: 30268148
[TBL] [Abstract][Full Text] [Related]
3. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
Dilokthornsakul P; Patidar M; Campbell JD
Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
[TBL] [Abstract][Full Text] [Related]
4. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
[TBL] [Abstract][Full Text] [Related]
5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
6. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
Tesell MA; Alper CJ; Bacon R; Greenwood BC; Lenz K; Jeffrey PL; Stevens K
J Manag Care Spec Pharm; 2019 Sep; 25(9):1021-1025. PubMed ID: 31456498
[TBL] [Abstract][Full Text] [Related]
7. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
[TBL] [Abstract][Full Text] [Related]
8. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
9. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.
Burgel PR; Munck A; Durieu I; Chiron R; Mely L; Prevotat A; Murris-Espin M; Porzio M; Abely M; Reix P; Marguet C; Macey J; Sermet-Gaudelus I; Corvol H; Bui S; Lemonnier L; Dehillotte C; Da Silva J; Paillasseur JL; Hubert D;
Am J Respir Crit Care Med; 2020 Jan; 201(2):188-197. PubMed ID: 31601120
[No Abstract] [Full Text] [Related]
10. Precision Medicine: At What Price?
Ferkol T; Quinton P
Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
[No Abstract] [Full Text] [Related]
11. Cystic fibrosis drug is not cost effective, says NICE.
Gulland A
BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
[No Abstract] [Full Text] [Related]
12. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.
Dilokthornsakul P; Hansen RN; Campbell JD
Eur Respir J; 2016 Jun; 47(6):1697-705. PubMed ID: 27126691
[TBL] [Abstract][Full Text] [Related]
13. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
14. Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France.
Olivereau L; Nave V; Garcia S; Perceval M; Rabilloud M; Durieu I; Reynaud Q
J Cyst Fibros; 2020 May; 19(3):402-406. PubMed ID: 31902692
[TBL] [Abstract][Full Text] [Related]
15. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation.
Wherry K; Williamson I; Chapman RH; Kuntz KM
Value Health; 2020 Oct; 23(10):1332-1339. PubMed ID: 33032777
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
19. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]